About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
Jul 16, 2020... REHOVOT, ISRAEL—July 16, 2020—Choosing the right drug for each cancer patient is key to successful treatment, but physicians currently have few reliable pointers to guide them in designing treatment protocols. Researchers at the Weizmann Institute of Science and the Broad Institute of MIT and Harvard have now developed a new method for selecting the best drug therapy for a given tumor, based on assigning scores to the cells’ internal messaging activities. In addition to helping physicians choose from a list of existing treatments, the method can help identify new molecular targets for the development of future drugs. In fact, the researchers have already used it to single out a gene that can be targeted for effectively treating breast cancers with a BRCA mutation. The study was recently published in Nature Communications.
https://www.weizmann-usa.org/blog/the-gender-of-medication/
Jul 29, 2020...
You wouldn’t give a toddler the same dose of ibuprofen that you, an adult – let’s assume you’re a woman – take. Likewise, should your dose be the same as a man’s?
It’s so clear when you take a moment to consider it; in the article “Should medicine be gendered?” (which also cites Weizmann Institute research), the BBC’s Science Focus nutshells it for us: “Men and women have completely different biologies, and yet doctors prescribe the same drugs and doses to everyone, regardless of sex.”
Aug 13, 2020... Prof. Eran Hornstein, a member of the steering committee for Weizmann’s new Institute for Brain and Neural Sciences, discusses this important flagship project, which will bring together experts in multiple disciplines to understand mental illness, advance treatments for diseases like Alzheimer's and Parkinson's, and much more. He explains why Weizmann is in an ideal position to uncover the brain's mysteries, with more than 40 internationally renowned research groups dedicated to addressing the most pressing topics in neuroscience.
https://www.weizmann-usa.org/blog/in-celebration-of-crispr/
Oct 29, 2020...
In February 2017, in Boston for the American Association for the Advancement of Science’s (AAAS’s) annual conference, The Curiosity Review snagged a chair in a packed ballroom of attendees.
The main attraction was Dr. Emmanuelle Charpentier. Then a rock star to scientists, today she is headline news; along with her longtime collaborator, Dr. Jennifer Doudna, Charpentier just received the 2020 Nobel Prize in Chemistry for the development of CRISPR. The method, which stands for “clustered regularly interspaced short palindromic repeats,” enables scientists to edit DNA.
https://www.weizmann-usa.org/news-media/in-the-news/the-cell-whisperer/
Nov 21, 2020... These are coronavirus days, and very few people can be seen in the narrow corridors of the Weizmann Institute of Science in Rehovot. We’re in the molecular immunology laboratory, located in one of the institute’s old buildings. It’s a simple place, the instruments are banal and dull. It looks like any lab in the world, one of thousands. But a miracle is occurring between the walls here. In the small details. The smallest.
https://www.weizmann-usa.org/news-media/news-releases/uncovering-the-anti-myeloma-resistance-files/
Feb 23, 2021... REHOVOT, ISRAEL—February 23, 2021—Multiple myeloma patients live much longer today than in the past, thanks to new targeted anti-myeloma drugs, but ultimately most people develop resistance to the medications, and in some the disease is resistant to therapy from the start. Weizmann Institute of Science researchers, in collaboration with physicians from Tel Aviv Sourasky Medical Center (TASMC), have made use of extremely sensitive genomic technology to reveal genetic pathways that characterize some of the more resistant cases of multiple myeloma. Their study, reported in Nature Medicine, may lead to a more informed, personalized treatment for these patients, and paves the way for using this new technology to discover disease targets in other cancers.
Feb 28, 2021...
Researchers from the Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center have found 30 genes that seem to be responsible for the resistance that multiple myeloma shows to treatment, which may help lead to more informed, personalized treatment for patients.
Malignant myeloma is a cancer of the antibody-producing plasma cells in bone marrow. Most patients develop resistance to medications and in some, the cancer is resistant to therapy from the start.
Apr 14, 2021... REHOVOT, ISRAEL—April 14, 2021—Being constantly hungry, no matter how much you eat – that’s the daily struggle of people with genetic defects in the brain’s appetite controls, and it often ends in severe obesity. In a study published in Science, researchers at the Weizmann Institute of Science, together with colleagues from the Queen Mary University of London and the Hebrew University of Jerusalem, have revealed the mechanism of action of the master switch for hunger in the brain: a receptor called melanocortin 4 (MC4). They have also clarified how this switch is activated by setmelanotide (brand name Imcivree), a drug recently approved for the treatment of severe obesity caused by certain genetic changes. The team’s findings shed new light on the way hunger is regulated and may help develop improved anti-obesity medications.
Apr 21, 2021...
Scientists may have discovered how a “switch” in the brain controls appetite, raising hopes for a new class of anti-obesity drugs.
Many people would like to lose a few pounds, with the temptation of favourite dishes and snacks often proving too much for our willpower.
For some, however, genetic defects cause them to feel famished no matter how much food they consume, resulting in severe obesity.
Dec 09, 2021... REHOVOT, ISRAEL—December 9, 2021—An exclusive “license” for making insulin in the human body belongs to the beta cells scattered throughout the pancreas. But because beta cells can become scarce or dysfunctional in people with diabetes, scientists have been searching for other cells that might be coaxed into manufacturing the vital glucose-regulating hormone. In a study published today in Nature Medicine, researchers from the Weizmann Institute of Science and from Yale School of Medicine discovered insulin-making cells in an unexpected place, the fetal intestine. This discovery may open up new directions in the future development of potential treatments for diabetes.
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
